[
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride tetracaine hydrochloride SODIUM CHLORIDE SODIUM ACETATE ACETIC ACID WATER TETRACAINE HYDROCHLORIDE TETRACAINE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. Discard unused portion. ( 2.1 ) 2.1 Topical Administration One drop topically in the eye as needed. Discard unused portion. 2.2 Sterile Field Administration Open package using standard aseptic technique. The DROP\u2011TAINER \u00ae dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP\u2011TAINER \u00ae dispenser and its contents are sterile."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Sterile ophthalmic solution containing 0.5% tetracaine hydrochloride ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "recent_major_changes": [
      "Warnings and Precautions ( 5.4 ) 2/2022",
      ""
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider: Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of TetracaineHydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration [ see Warnings and Precautions ( 5.2 )]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal injury with Intracameral Use [See Warnings and Precautions (5.1) ] Corneal Toxicity [See Warnings and Precautions (5.2) ] Corneal Injury due to Insensitivity [ See Warnings and Precautions (5.3) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: stinging, burning, conjunctival redness ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc., at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available. 8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including TetracaineHydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss. Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u2022 HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82. Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5. Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Inactive ingredients: sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP Chemical Diagram"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of tetracainehydrochloride ophthalmic solution results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing. [see Corneal toxicity (5.2) and Overdosage (10) ] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI-UNITS\u00ae is supplied as single patient use, 4 mL filled in 4-mL natural medium- or low-density polyethylene plastic DROP-TAINER\u00ae dispensers and natural low-density polyethylene tips with white polypropylene caps in a carton of 12. Each sterilized DROP-TAINER\u00ae dispenser is packaged in a clear PVC and Tyvek blister. This product does not contain a preservative; discard unused portion. NDC: 70518-4183-00 NDC: 70518-4183-01 PACKAGING: 12 in 2 CARTON PACKAGING: 1-4 mL BOTTLE, DROPPER TYPE 0 Storage: Store at 2\u00b0C to 25\u00b0C (36\u00b0F to 77\u00b0F). Protect from light. Do not use if solution contains crystals, is cloudy, or discolored. Repackaged and Distributed By: Remedy Repack, Inc. 625 Kolter Dr. Suite #4 Indiana, PA 1-724-465-8762"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries. Repackaged By / Distributed By: RemedyRepack Inc. 625 Kolter Drive, Indiana, PA 15701 (724) 465-8762"
    ],
    "package_label_principal_display_panel": [
      "DRUG: Tetracaine Hydrochloride GENERIC: tetracaine hydrochloride DOSAGE: SOLUTION ADMINSTRATION: OPHTHALMIC NDC: 70518-4183-0 NDC: 70518-4183-1 PACKAGING: 4 mL in 1 BOTTLE, DROPPER OUTER PACKAGING: 12 in 1 CARTON ACTIVE INGREDIENT(S): Tetracaine Hydrochloride 5mg in 1mL INACTIVE INGREDIENT(S): Sodium Chloride Sodium Acetate Acetic Acid Water MM1 MM2"
    ],
    "set_id": "01fba5f8-a60a-444c-9abd-299540b8815a",
    "id": "35bf62a6-b5a0-9582-e063-6394a90a1b92",
    "effective_time": "20250522",
    "version": "2",
    "openfda": {
      "application_number": [
        "NDA208135"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "REMEDYREPACK INC."
      ],
      "product_ndc": [
        "70518-4183"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "35bf62a6-b5a0-9582-e063-6394a90a1b92"
      ],
      "spl_set_id": [
        "01fba5f8-a60a-444c-9abd-299540b8815a"
      ],
      "package_ndc": [
        "70518-4183-1",
        "70518-4183-0"
      ],
      "original_packager_product_ndc": [
        "0065-0741"
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride tetracaine hydrochloride TETRACAINE HYDROCHLORIDE TETRACAINE Sodium Chloride Sodium Acetate Acetic Acid AQUA Chemical Diagram"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. Discard unused portion. ( 2.1 ) 2.1 Topical Administration One drop topically in the eye as needed. Discard unused portion. 2.2 Sterile Field Administration Open package using standard aseptic technique. The DROP\u2011TAINER \u00ae dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP\u2011TAINER \u00ae dispenser and its contents are sterile."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Sterile ophthalmic solution containing 0.5% tetracaine hydrochloride ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "recent_major_changes": [
      "Warnings and Precautions ( 5.4 ) 2/2022",
      ""
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider: Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of TetracaineHydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration [ see Warnings and Precautions ( 5.2 )]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal injury with Intracameral Use [See Warnings and Precautions (5.1) ] Corneal Toxicity [See Warnings and Precautions (5.2) ] Corneal Injury due to Insensitivity [ See Warnings and Precautions (5.3) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: stinging, burning, conjunctival redness ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc., at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available. 8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including TetracaineHydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss. Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u2022 HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82. Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5. Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Inactive ingredients: sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of tetracainehydrochloride ophthalmic solution results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing. [see Corneal toxicity (5.2) and Overdosage (10) ] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Product: 50090-2364 NDC: 50090-2364-1 4 mL in a BOTTLE, DROPPER"
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries. ALCON \u00ae Distributed by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA \u00a9 2022 Alcon Inc. 300055204-1121"
    ],
    "package_label_principal_display_panel": [
      "tetracaine hydrochloride Label Image"
    ],
    "set_id": "23c40ef8-6338-46f8-aca9-1aa4f3b2207b",
    "id": "c7b72c56-5267-471a-8370-55a0f0122e5f",
    "effective_time": "20250211",
    "version": "9",
    "openfda": {
      "application_number": [
        "NDA208135"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "A-S Medication Solutions"
      ],
      "product_ndc": [
        "50090-2364"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "c7b72c56-5267-471a-8370-55a0f0122e5f"
      ],
      "spl_set_id": [
        "23c40ef8-6338-46f8-aca9-1aa4f3b2207b"
      ],
      "package_ndc": [
        "50090-2364-1"
      ],
      "original_packager_product_ndc": [
        "0065-0741"
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride tetracaine hydrochloride Tetracaine Hydrochloride Tetracaine Sodium Chloride Sodium Acetate Acetic Acid Water Chemical Diagram label Carton Label Carton Label blister"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. Discard unused portion. ( 2.1 ) 2.1 Topical Administration One drop topically in the eye as needed. Discard unused portion. 2.2 Sterile Field Administration Open package using standard aseptic technique. The DROP\u2011TAINER \u00ae dispenser may then be allowed to fall upon a sterile surface. The entire outer surface of the DROP\u2011TAINER \u00ae dispenser and its contents are sterile."
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Sterile ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Sterile ophthalmic solution containing 0.5% tetracaine hydrochloride ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS None. None ( 4 )"
    ],
    "recent_major_changes": [
      "Warnings and Precautions ( 5.4 ) 2/2022",
      ""
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider: Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of TetracaineHydrochloride Ophthalmic Solution 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution 0.5% is not intended for patient self-administration [ see Warnings and Precautions ( 5.2 )]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal injury with Intracameral Use [See Warnings and Precautions (5.1) ] Corneal Toxicity [See Warnings and Precautions (5.2) ] Corneal Injury due to Insensitivity [ See Warnings and Precautions (5.3) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: stinging, burning, conjunctival redness ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Alcon Laboratories, Inc., at 1-800-757-9195 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution 0.5% or from the underlying maternal condition. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution 0.5% on fertility are available. 8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including TetracaineHydrochloride Ophthalmic Solution 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss. Symptoms related to systemic toxicity consist mainly of effects on the neurologic and cardiovascular systems."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-,2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u2022 HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder and has a molecular weight of 300.82. Tetracaine Hydrochloride Ophthalmic Solution 0.5% has a pH of 3.7 to 5.5. Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Inactive ingredients: sodium chloride, sodium acetate trihydrate, acetic acid (to adjust pH approximately 4.5), Water for Injection, USP"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of tetracainehydrochloride ophthalmic solution results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing. [see Corneal toxicity (5.2) and Overdosage (10) ] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution 0.5% STERI-UNITS \u00ae is supplied as single patient use, 4 mL filled in 4-mL natural medium- or low-density polyethylene plastic DROP-TAINER \u00ae dispensers and natural low-density polyethylene tips with white polypropylene caps in a carton of 12. Each sterilized DROP-TAINER \u00ae dispenser is packaged in a clear PVC and Tyvek blister. This product does not contain a preservative; discard unused portion. NDC 0065-0741-14 Storage: Store at 2\u00b0C to 25\u00b0C (36\u00b0F to 77\u00b0F). Protect from light. Do not use if solution contains crystals, is cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive up to 20 minutes and that care should be taken to avoid accidental injuries. ALCON \u00ae Distributed by: ALCON LABORATORIES, INC. Fort Worth, Texas 76134 USA \u00a9 2022 Alcon Inc. 300055204-1121"
    ],
    "package_label_principal_display_panel": [
      "PRINCIPAL DISPLAY PANEL NDC 0065-0741-14 Tetracaine Hydrochloride Ophthalmic Solution, 0.5% STERi-UNITS Single Dose DROP-TAINER\u00ae dispensers for topical use.See package insert for directions. Rx Only 12 x 4mL STERILE Alcon Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA Printed in USA NDC 0065-0741-14 TETRACAINE HYDROCHLORIDE Ophthalmic Solution 0.5% INGREDIENTS: Each mL contains: Active: Tetracaine Hydrochloride 0.5%. (equivalent to tetracaine (0.44%) Inactive: Sodium Chloride, Sodium Acetate Trihydrate, Acetic Acid (to adjust pH), Water for Injection. USUAL DOSAGE: One drop topically in the eye(s) as needed. Discard unused portion. STORAGE: Store at 2\u00b0C to 25\u00b0C (36\u00b0F to 77\u00b0F). Protect from Light. Do not use if discolored Printed in USA 300057714-0622 GTIN: 10300650741146 SN: LOT: EXP: PRINCIPAL DISPLAY PANEL NDC 0065-0741-14 Tetracaine Hydrochloride Ophthalmic Solution, 0.5% STERi-UNITS Single Dose DROP-TAINER\u00ae dispensers for topical use.See package insert for directions. Rx Only 12 x 4mL STERILE Alcon Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA Product of Switzerland Printed in USA NDC 0065-0741-14 TETRACAINE HYDROCHLORIDE Ophthalmic Solution 0.5% INGREDIENTS: Each mL contains: Active: Tetracaine Hydrochloride 0.5%. (equivalent to tetracaine (0.44%) Inactive: Sodium Chloride, Sodium Acetate Trihydrate, Acetic Acid (to adjust pH), Water for Injection. USUAL DOSAGE: One drop topically in the eye(s) as needed. Discard unused portion. STORAGE: Store at 2\u00b0C to 25\u00b0C (36\u00b0F to 77\u00b0F). Protect from Light. Do not use if discolored Printed in USA GTIN: 10300650741146 SN: LOT: EXP: 300057715-0622 NDC 0065-0741-14 TETRACAINE HYDROCHLORIDE Ophthalmic Solution 0.5% 4mL Rx Only SINGLE DOSE UNIT \u2013DISCARD UNUSED PORTION H14660-0916 LOT: EXP : TETRACAINE HYDROCHLORIDE OPHTHALMIC SOLUTION 0.5% 4mL STERILE UNTIL OPENED PROTECT FROM LIGHT Rx Only NDC 0065-0741-14 300065025-1223 Alcon Laboratories, Inc. Fort Worth, Texas 76134 USA Alcon LOT: EXP.:"
    ],
    "set_id": "5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79",
    "id": "e5c0f202-3d32-4b47-8d45-e1d031ff7ce9",
    "effective_time": "20240119",
    "version": "14",
    "openfda": {
      "application_number": [
        "NDA208135"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Alcon Laboratories, Inc."
      ],
      "product_ndc": [
        "0065-0741"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "e5c0f202-3d32-4b47-8d45-e1d031ff7ce9"
      ],
      "spl_set_id": [
        "5c7b1de4-9f55-1d0e-ef6d-b0ba2cbaba79"
      ],
      "package_ndc": [
        "0065-0741-12",
        "0065-0741-14"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0300650741149"
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride Tetracaine Hydrochloride CHLOROBUTANOL BORIC ACID POTASSIUM CHLORIDE EDETATE DISODIUM WATER SODIUM HYDROXIDE HYDROCHLORIC ACID TETRACAINE HYDROCHLORIDE TETRACAINE"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. ( 2 )"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Sterile, preserved, ophthalmic solution containing 0.5% tetracaine hydrochloride. ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, should not be used in patients with a history of hypersensitivity to any component of this preparation. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) 5.1 Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [See Warnings and Precautions ( 5.1 )] Corneal Toxicity [See Warnings and Precautions ( 5.2 )] Corneal Injury due to Insensitivity [See Warnings and Precautions ( 5.3 )] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch Health US, LLC at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available. 8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C15H24N2O2 \u2022 HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.82 Active ingredient : tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative : chlorobutanol 0.4% Inactive ingredients : boric acid, potassium chloride, edetate disodium dihydrate, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 \u2013 6.0). chemstructure.jpg"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing. [See Warnings and Precautions ( 5.2 ) and Overdosage ( 10 )]."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 0187-920-05 5 mL in a 7.5 mL Bottle After opening, this product can be used until the expiration date stamped on the bottle. Storage : Store at 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries. Distributed by: Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA \u00a9 2020 Bausch Health Companies Inc. or its affiliates 9xxxxxx (Folded) 9xxxxxx (Flat)"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Carton 5 mL NDC 0187-0920-05 Rx only Tetracaine Hydrochloride Ophthalmic Solution, USP 0.05% (Sterile) 5 mL BAUSCH Health C:\\Users\\dale.iannetti\\OneDrive - Valeant Pharmaceuticals North America, LLC\\Documents\\SPL Assignments\\2020\\Tetracaine B&L\\carton.jpg"
    ],
    "set_id": "78404c9e-9c31-4b0a-90f4-04182e82e183",
    "id": "453da1ac-7306-7a40-e063-6394a90a741c",
    "effective_time": "20251205",
    "version": "2",
    "openfda": {
      "application_number": [
        "NDA210821"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Bausch Health US LLC"
      ],
      "product_ndc": [
        "0187-0920"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "453da1ac-7306-7a40-e063-6394a90a741c"
      ],
      "spl_set_id": [
        "78404c9e-9c31-4b0a-90f4-04182e82e183"
      ],
      "package_ndc": [
        "0187-0920-05"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride Tetracaine Hydrochloride CHLOROBUTANOL BORIC ACID POTASSIUM CHLORIDE EDETATE DISODIUM WATER SODIUM HYDROXIDE HYDROCHLORIC ACID TETRACAINE HYDROCHLORIDE TETRACAINE"
    ],
    "recent_major_changes": [
      "Warnings and Precautions (5.4) 2/2022"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. ( 2 )"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Ophthalmic solution containing 0.5% tetracaine hydrochloride. ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury Due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration [see Warnings and Precautions ( 5.2 )]."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [ see Warnings and Precautions ( 5.1 )] Corneal Toxicity [ see Warnings and Precautions ( 5.2 )] Corneal Injury Due to Insensitivity [ see Warnings and Precautions ( 5.3 )] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Oceanside Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available. 8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u25cf HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.82 Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative: chlorobutanol 0.4% Inactive ingredients: boric acid, potassium chloride, edetate disodium dihydrate, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 \u2013 6.0). CHEM"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing [ see Warnings and Precautions ( 5.2 ) and Overdosage ( 10 )] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 68682-920-64 15 mL in a 15 mL Bottle NDC 68682-920-05 5 mL in a 7.5 mL Bottle After opening, this product can be used until the expiration date stamped on the bottle. Storage: Store at 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries. Distributed by: Oceanside Pharmaceuticals, a division of Bausch Health US, LLC Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA \u00a9 2022 Bausch Health Companies Inc. or its affiliates 9675203 (Folded) 9675303 (Flat)"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL NDC 68682-920-64 Rx only Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% (Sterile) 15 mL OCEANSIDE PHARMACEUTICALS carton.jpg"
    ],
    "set_id": "807dae5d-f34a-4f3d-9f54-dd350b056a92",
    "id": "48ec9821-6f9b-2a1b-e063-6394a90a1d98",
    "effective_time": "20260121",
    "version": "6",
    "openfda": {
      "application_number": [
        "NDA210821"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Oceanside Pharmaceuticals"
      ],
      "product_ndc": [
        "68682-920"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "48ec9821-6f9b-2a1b-e063-6394a90a1d98"
      ],
      "spl_set_id": [
        "807dae5d-f34a-4f3d-9f54-dd350b056a92"
      ],
      "package_ndc": [
        "68682-920-64",
        "68682-920-05"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride Tetracaine Hydrochloride CHLOROBUTANOL BORIC ACID POTASSIUM CHLORIDE EDETATE DISODIUM WATER SODIUM HYDROXIDE HYDROCHLORIC ACID TETRACAINE HYDROCHLORIDE TETRACAINE"
    ],
    "recent_major_changes": [
      "Warnings and Precautions ( 5.4 ) 02/2022"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. ( 2 )"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Ophthalmic solution containing 0.5% tetracaine hydrochloride ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury Due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration [see Warnings and Precautions (5.2) ] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [see Warnings and Precautions (5.1) ] Corneal Toxicity [see Warnings and Precautions (5.2) ] Corneal Injury Due to Insensitivity [see Warnings and Precautions (5.3) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available. 8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u25cf HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.83. Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative: chlorobutanol 0.4% Inactive ingredients: boric acid, edetate disodium dihydrate, potassium chloride, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 \u2013 6.0). chemstructure"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing [see Warnings and Precautions (5.2) and Overdosage (10) ] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 24208-092-15 15 mL in a 15 mL Bottle NDC 24208-092-05 5 mL in a 7.5 mL Bottle After opening, this product can be used until the expiration date stamped on the bottle. Storage: Store at 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA \u00a9 2022 Bausch & Lomb Incorporated or its affiliates 9781000 (Folded) 9781100 (Flat)"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL- Carton 15 mL NDC 24208-092-15 Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% (Sterile) FOR OPHTHALMIC USE Rx only 15 mL BAUSCH + LOMB 9780901 carton"
    ],
    "set_id": "8352a2c8-15e7-4719-ac06-df10ff6b0568",
    "id": "203808bf-ce0e-8780-e063-6294a90a5a9f",
    "effective_time": "20240821",
    "version": "3",
    "openfda": {
      "application_number": [
        "NDA210821"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Bausch & Lomb Incorporated"
      ],
      "product_ndc": [
        "24208-092"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "203808bf-ce0e-8780-e063-6294a90a5a9f"
      ],
      "spl_set_id": [
        "8352a2c8-15e7-4719-ac06-df10ff6b0568"
      ],
      "package_ndc": [
        "24208-092-05",
        "24208-092-15"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride Tetracaine Hydrochloride TETRACAINE HYDROCHLORIDE TETRACAINE CHLOROBUTANOL BORIC ACID EDETATE DISODIUM POTASSIUM CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER Tetracaine Hydrochloride Tetracaine Hydrochloride TETRACAINE HYDROCHLORIDE TETRACAINE CHLOROBUTANOL BORIC ACID EDETATE DISODIUM POTASSIUM CHLORIDE SODIUM HYDROXIDE HYDROCHLORIC ACID WATER"
    ],
    "recent_major_changes": [
      "RECENT MAJOR CHANGES Warnings and Precautions (5.4) 2/2022"
    ],
    "recent_major_changes_table": [
      "<table ID=\"ID2\" width=\"246\" styleCode=\"Noautorules\"><col width=\"189\"/><col width=\"57\"/><tbody><tr><td valign=\"top\" align=\"left\"> Warnings and Precautions (5.4)  </td><td valign=\"top\" align=\"left\"> 2/2022 </td></tr></tbody></table>"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine hydrochloride ophthalmic solution, 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine hydrochloride ophthalmic solution, 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. (1)"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. (2)"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Tetracaine hydrochloride ophthalmic solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Ophthalmic solution containing 0.5% tetracaine hydrochloride. (3)"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Tetracaine hydrochloride ophthalmic solution, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine hydrochloride ophthalmic solution, 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. (4)"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. (5.1) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. (5.2) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. (5.3) For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self- administration. (5.4) 5.1 Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of tetracaine hydrochloride ophthalmic solution, 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury Due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine hydrochloride ophthalmic solution, 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, 0.5% is not intended for patient self-administration [see Warnings and Precautions (5.2)] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [ see Warnings and Precautions (5.1)] Corneal Toxicity [ see Warnings and Precautions ( 5.2)] Corneal Injury Due to Insensitivity [ see Warnings and Precautions ( 5.3)] The following adverse reactions have been identified following use of tetracaine hydrochloride ophthalmic solution, 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. (6) To report SUSPECTED ADVERSE REACTIONS, contact Somerset Therapeutics, LLC at +1 800-417-9175 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether tetracaine hydrochloride ophthalmic solution, 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for tetracaine hydrochloride ophthalmic solution, 0.5% and any potential adverse effects on the breastfed child from tetracaine hydrochloride ophthalmic solution, 0.5%. 8.3 Females and Males of Reproductive Potential No human data on the effect of tetracaine hydrochloride ophthalmic solution, 0.5% on fertility are available. 8.4 Pediatric Use Safety of tetracaine hydrochloride ophthalmic solution, 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution, 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution, 0.5% have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with tetracaine hydrochloride ophthalmic solution, 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety of tetracaine hydrochloride ophthalmic solution, 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of tetracaine hydrochloride ophthalmic solution, 0.5% for use in pediatric patients has been extrapolated from adequate and well controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of tetracaine hydrochloride ophthalmic solution, 0.5% have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including tetracaine hydrochloride ophthalmic solution, 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine hydrochloride ophthalmic solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u25cf HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a white crystalline powder with a molecular weight of 300.82 Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative: chlorobutanol 0.4% Inactive ingredients: boric acid, potassium chloride, edetate disodium dihydrate, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 \u2013 6.0). Image"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of tetracaine hydrochloride ophthalmic solution, 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of tetracaine hydrochloride ophthalmic solution, 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of tetracaine hydrochloride ophthalmic solution, 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing [ see Warnings and Precautions ( 5.2) and Overdosage (10)] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine hydrochloride ophthalmic solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a white LDPE bottle, plugged with white LDPE nozzle and capped with white HDPE cap in the following sizes: NDC 70069-596-01, 5 mL fill in 5 mL Bottle NDC 70069-597-01, 15 mL fill in 15 mL Bottle After opening, this product can be used until the expiration date stamped on the bottle. Storage: Store at 15\u00b0 to 25\u00b0C (59\u00b0 to 77\u00b0F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries."
    ],
    "spl_unclassified_section": [
      "SPL UNCLASSIFIED Manufactured for: Somerset Therapeutics, LLC Somerset, NJ 08873 Made in India Code No.: KR/DRUGS/KTK/28/289/97 ST-TEC/P/00 1200992"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE LABEL.PRINCIPAL DISPLAY PANEL Container Label NDC 70069-596-01 Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile Rx only 5 mL Carton Label NDC 70069-596-01 Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile Rx only 5 mL Container Label NDC 70069-597-01 Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile Rx only 15 mL Carton Label NDC 70069-597-01 Tetracaine Hydrochloride Ophthalmic Solution USP, 0.5% Sterile Rx only 15 mL Image Image Image Image"
    ],
    "set_id": "bab63a18-3069-48a1-896e-433725f1dbaf",
    "id": "8d8c6ec7-7369-4f34-88bf-e8827fb87ef0",
    "effective_time": "20241221",
    "version": "2",
    "openfda": {
      "application_number": [
        "ANDA217227"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Somerset Therapeutics, LLC"
      ],
      "product_ndc": [
        "70069-596",
        "70069-597"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "8d8c6ec7-7369-4f34-88bf-e8827fb87ef0"
      ],
      "spl_set_id": [
        "bab63a18-3069-48a1-896e-433725f1dbaf"
      ],
      "package_ndc": [
        "70069-596-01",
        "70069-597-01"
      ],
      "is_original_packager": [
        true
      ],
      "upc": [
        "0370069596012",
        "0370069597019"
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  },
  {
    "spl_product_data_elements": [
      "Tetracaine Hydrochloride Tetracaine Hydrochloride CHLOROBUTANOL BORIC ACID POTASSIUM CHLORIDE EDETATE DISODIUM WATER SODIUM HYDROXIDE HYDROCHLORIC ACID TETRACAINE HYDROCHLORIDE TETRACAINE"
    ],
    "recent_major_changes": [
      "Warnings and Precautions ( 5.4 ) 02/2022"
    ],
    "indications_and_usage": [
      "1 INDICATIONS AND USAGE Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%, is an ester local anesthetic indicated for procedures requiring a rapid and short-acting topical ophthalmic anesthetic. ( 1 )"
    ],
    "dosage_and_administration": [
      "2 DOSAGE AND ADMINISTRATION One drop topically in the eye(s) as needed. One drop topically in the eye(s) as needed. ( 2 )"
    ],
    "dosage_forms_and_strengths": [
      "3 DOSAGE FORMS AND STRENGTHS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a clear, colorless, ophthalmic solution containing 0.5% w/v tetracaine hydrochloride equivalent to tetracaine 0.44% w/v. Ophthalmic solution containing 0.5% tetracaine hydrochloride ( 3 )"
    ],
    "contraindications": [
      "4 CONTRAINDICATIONS Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% should not be used in patients with a history of hypersensitivity to any component of this preparation. ( 4 )"
    ],
    "warnings_and_cautions": [
      "5 WARNINGS AND PRECAUTIONS Do not use intracamerally since use may damage corneal endothelial cells. ( 5.1 ) Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. ( 5.2 ) Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. ( 5.3 ) For Administration by Healthcare Provider : Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration. ( 5.4 ) 5.1 Corneal Injury with Intracameral Use Not for injection or intraocular use. Do not use intracamerally because use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may lead to damage of the corneal endothelial cells. 5.2 Corneal Toxicity Prolonged use or abuse may lead to corneal epithelial toxicity and may manifest as epithelial defects which may progress to permanent corneal damage. 5.3 Corneal Injury Due to Insensitivity Patients should not touch the eye for at least 10-20 minutes after using anesthetic as accidental injuries can occur due to insensitivity of the eye. 5.4 For Administration by Healthcare Provider Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is indicated for administration under the direct supervision of a healthcare provider. Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is not intended for patient self-administration [see Warnings and Precautions (5.2) ] ."
    ],
    "adverse_reactions": [
      "6 ADVERSE REACTIONS The following serious ocular adverse reactions are described elsewhere in the labeling: Corneal Injury with Intracameral Use [see Warnings and Precautions (5.1) ] Corneal Toxicity [see Warnings and Precautions (5.2) ] Corneal Injury Due to Insensitivity [see Warnings and Precautions (5.3) ] The following adverse reactions have been identified following use of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Ocular Adverse Reactions Transient stinging, burning, and conjunctival redness, eye irritation, eye pain, ocular discomfort. Ocular adverse events: transient stinging, burning, conjunctival redness, eye irritation, eye pain, ocular discomfort. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Bausch & Lomb Incorporated at 1-800-553-5340 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch."
    ],
    "use_in_specific_populations": [
      "8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature. 8.2 Lactation Risk Summary There are no data to assess whether Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is excreted in human milk or to assess its effects on milk production/excretion. The developmental and health benefits of breastfeeding should be considered along with the mother\u2019s clinical need for Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% and any potential adverse effects on the breastfed child from Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5%. 8.3 Females and Males of Reproductive Potential No human data on the effect of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% on fertility are available. 8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population. 8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "pregnancy": [
      "8.1 Pregnancy Risk Summary There are no adequate and well-controlled studies with Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in pregnant women. Animal developmental and reproductive toxicity studies with tetracaine hydrochloride have not been reported in the published literature."
    ],
    "pediatric_use": [
      "8.4 Pediatric Use Safety of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% in the pediatric population has been demonstrated in clinical trials. Efficacy of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% for use in pediatric patients has been extrapolated from adequate and well-controlled clinical trials in the adult population."
    ],
    "geriatric_use": [
      "8.5 Geriatric Use No overall differences in safety or effectiveness of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% have been observed between elderly and younger patients."
    ],
    "overdosage": [
      "10 OVERDOSAGE Prolonged use of a topical ocular anesthetic including Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% may produce permanent corneal opacification and ulceration with accompanying visual loss."
    ],
    "description": [
      "11 DESCRIPTION Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is a sterile, clear, colorless, topical local anesthetic for ophthalmic use only containing tetracaine hydrochloride as the active pharmaceutical ingredient. Tetracaine hydrochloride is chemically designated as benzoic acid, 4-(butylamino)-, 2-(dimethylamino) ethyl ester, monohydrochloride. Its chemical formula is C 15 H 24 N 2 O 2 \u25cf HCl and it is represented by the chemical structure: Tetracaine hydrochloride is a fine, white, crystalline, odorless powder with a molecular weight of 300.83. Active ingredient: tetracaine hydrochloride 0.5% w/v (equivalent to 0.44% w/v tetracaine) Preservative: chlorobutanol 0.4% Inactive ingredients: boric acid, edetate disodium dihydrate, potassium chloride, water for injection. Sodium hydroxide and/or hydrochloric acid may be added to adjust pH (3.7 \u2013 6.0). CHEM"
    ],
    "clinical_pharmacology": [
      "12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia. 12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "mechanism_of_action": [
      "12.1 Mechanism of Action Tetracaine blocks sodium ion channels required for the initiation and conduction of neuronal impulses thereby affecting local anesthesia."
    ],
    "pharmacokinetics": [
      "12.3 Pharmacokinetics The systemic exposure to tetracaine following topical ocular administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% has not been studied. Tetracaine hydrochloride is metabolized by plasma pseudocholinesterases and nonspecific esterases in ocular tissues."
    ],
    "nonclinical_toxicology": [
      "13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "carcinogenesis_and_mutagenesis_and_impairment_of_fertility": [
      "13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Studies to assess the genotoxicity of tetracaine hydrochloride have not been reported in the published literature. Long-term animal studies have not been conducted to evaluate the carcinogenic potential of tetracaine hydrochloride. Animal studies to assess the effects of tetracaine hydrochloride on fertility have not been reported in the published literature."
    ],
    "clinical_studies": [
      "14 CLINICAL STUDIES Topical administration of Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% results in localized temporary anesthesia. The maximum effect is achieved within 10\u201320 seconds after instillation, with efficacy lasting 10\u201320 minutes. Duration of effect can be extended with repeated dosing [see Warnings and Precautions (5.2) and Overdosage (10) ] ."
    ],
    "how_supplied": [
      "16 HOW SUPPLIED/STORAGE AND HANDLING Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% is supplied as a sterile, aqueous, topical ophthalmic solution in a low-density polyethylene plastic dropper bottle with a low-density polyethylene dropper tip and white polypropylene cap in the following sizes: NDC 82260-920-15 15 mL in a 15 mL Bottle NDC 82260-920-05 5 mL in a 7.5 mL Bottle After opening, this product can be used until the expiration date stamped on the bottle. Storage: Store at 15\u00b0C to 25\u00b0C (59\u00b0F to 77\u00b0F). Protect from light. Do not use if solution contains crystals, cloudy, or discolored."
    ],
    "information_for_patients": [
      "17 PATIENT COUNSELING INFORMATION Eye Care Precaution Do not touch the dropper tip to any surface as this may contaminate the solution. Advise patients that, due to the effect of the anesthetic, their eyes will be insensitive for up to 20 minutes and that care should be taken to avoid accidental injuries. Distributed by: Bausch & Lomb Americas Inc. Bridgewater, NJ 08807 USA Manufactured by: Bausch & Lomb Incorporated Tampa, FL 33637 USA \u00a9 2022 Bausch & Lomb Incorporated or its affiliates 9780400 (Folded) 9780500 (Flat)"
    ],
    "package_label_principal_display_panel": [
      "PACKAGE/LABEL PRINCIPAL DISPLAY PANEL \u2013 15 mL carton NDC 82260-920-15 Tetracaine Hydrochloride Ophthalmic Solution, USP 0.5% (Sterile) FOR OPHTHALMIC USE [EYE IMAGE] Rx only 15 mL BAUSCH + LOMB 9780301 MA09111 CARTON"
    ],
    "set_id": "f12d5944-0d6c-43ff-89fd-e0b5669e9b4a",
    "id": "4a468703-7613-0c8b-e063-6294a90a2f6e",
    "effective_time": "20260207",
    "version": "4",
    "openfda": {
      "application_number": [
        "NDA210821"
      ],
      "brand_name": [
        "Tetracaine Hydrochloride"
      ],
      "generic_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "manufacturer_name": [
        "Bausch & Lomb Americas Inc."
      ],
      "product_ndc": [
        "82260-920"
      ],
      "product_type": [
        "HUMAN PRESCRIPTION DRUG"
      ],
      "route": [
        "OPHTHALMIC"
      ],
      "substance_name": [
        "TETRACAINE HYDROCHLORIDE"
      ],
      "rxcui": [
        "1547771"
      ],
      "spl_id": [
        "4a468703-7613-0c8b-e063-6294a90a2f6e"
      ],
      "spl_set_id": [
        "f12d5944-0d6c-43ff-89fd-e0b5669e9b4a"
      ],
      "package_ndc": [
        "82260-920-05",
        "82260-920-15"
      ],
      "is_original_packager": [
        true
      ],
      "unii": [
        "5NF5D4OPCI"
      ]
    }
  }
]